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Abstract
PURPOSE: The purpose of this study was to evaluate
the possible use of changes in apparent diffusion co-
efficient (ADC) measured by magnetic resonance im-
aging for pretreatment prediction and early detection
of tumor response in a mouse model during fractio-
nated chemoradiotherapy. MATERIALS AND METH-
ODS: Athymic mice with bilateral HT29 xenografts on
rear flanks were allocated into three groups: control,
capecitabine, and capecitabine and oxaliplatin. The
left flanks of the mice received daily irradiation. T2
and diffusion images were acquired before therapy
and weekly for the following 9 weeks. Pretreatment and
changes in ADC were calculated and compared with
tumor doubling growth delay. RESULTS: No correla-
tions between pretreatment ADC and changes in tumor
volumes after therapy were seen. All treated tumors,
except those receiving capecitabine (P = .06), showed
increased mean tumor ADC values 11 days after ini-
tialization of therapy (P < .05) before returning to pre-
treatment valueswithin 5 days posttherapy (day 18 after
onset of therapy). This increase in mean tumor ADC
showed a strong positive correlation (r = 0.92, P < .01)
with mean tumor doubling growth delay. CONCLU-
SIONS: Pretreatment ADC values did not predict the ef-
fectiveness of therapy, whereas early changes in mean
ADC quantitatively correlated with treatment outcome.
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Introduction
Colorectal cancer is estimated to be the second leading
cause of cancer deaths worldwide [1]. Approximately 35%
of colorectal cancers are located in the rectum, and progno-
sis depends on the tumor’s degree of penetration through
the bowel wall, lymph node involvement, and existence of
distant metastasis. Treatment advances, such as the stan-
dardized surgical technique of total mesorectal excision [2]
and preoperative radiotherapy with or without concomitant sys-
temic chemotherapy, have decreased the previously high
local recurrence rate and have improved survival in rectal
cancer patients [3–6]. Despite these advances, about 40% of
patients die from disseminated disease. Early markers of
therapy response have the potential to enable oncologists to
adjust therapeutic intervention during the course of treatment,
giving a potential for improved survival for these patients.
Diffusion-weighted magnetic resonance imaging (DW-MRI)
provides information about the tissue microenvironment and
is able to detect molecular and cellular changes preceding
macroscopic changes in tumor size, regression, and growth
[7–13]. The diffusion of water in tissue may be assessed by
apparent diffusion coefficient (ADC) measured by DW-MRI. In
DW-MRI, MR signal is made dependent on water mobility by
incorporating a set of additional bipolar pulsed magnetic field
gradients into the MR sequence [14]. Individual water protons
(spins) will accumulate a phase shift proportional to their
position in the gradient field. After waiting for an evolution time
for water protons to diffuse, an inverse refocusing gradient is
applied. Stationary water protons are completely refocused,
whereas the refocusing of mobile water protons is incomplete.
Signal intensity in diffusion-weighted images depends on
b value. For the commonly used pulsed gradient spin-echo
diffusion sensitization scheme, the b value is given by b =
c2d2G2(D  d/3), where c is the gyromagnetic ratio, G is the
magnitude of diffusion-encoding gradients, d is the duration of
each diffusion-encoding gradient, and D is the time interval
between diffusion-encoding gradients. Thus, the MR signal is
made proportional to local tissue water mobility. The diffusion of
water in tissue is strongly affected by molecular viscosity and
membrane permeability between intracellular and extracellular
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compartments, active transport and flow, and directionality
of structures that impede or enhance water mobility [8,9].
Recent work has demonstrated that the ADC value of a tis-
sue is strongly dependent on microscopic changes in tissue
structure and physiology [15], and several groups have
shown increased water diffusion in experimental tumors
as a response to successful therapies [7–13]. This increase
is most likely due to a shift of water from the intracellular
space to the extracellular space [8,9]. As cells are killed
by therapeutic interventions, the integrity of cell membranes
may be compromised, and the fractional volume of inter-
stitial space is increased due to apoptosis-induced cell
shrinkage and necrosis. Damage to tissue microvasculature
may also lead to vasogenic edema, thereby reducing the
viscosity of interstitial fluid and increasing extracellular vol-
ume. A reduced cell volume fraction will result in an overall
increase in ADC because water molecules in the extra-
cellular space move more freely than water protons in the
intracellular space [9].
More than 40 years after its development, 5-fluorouracil
(5-FU) remains the most used chemotherapeutic agent for
the treatment of many types of cancer; for locally advanced
rectal cancer, 5-FU is the standard radiosensitizing agent
[16]. Data from phase I/II single-agent and combination
capecitabine chemoradiation studies provide a clear ratio-
nale for replacing infusional 5-FUwith the orally administered
5-FU prodrug capecitabine as part of chemoradiation for
patients with locally advanced rectal cancer [17]. The avail-
ability of new radiosensitizing drugs that may be combined
with 5-FU offers an opportunity to improve the effectiveness
of therapy, and there are several clinical studies evaluating
the effect of integrating oxaliplatin into the treatment regime
for locally advanced rectal cancer [18–24]. Capecitabine and
oxaliplatin both possess radiosensitizing properties [25–28],
and several phase I and phase II studies indicate that pre-
operative capecitabine/oxaliplatin chemoradiation is effective
and generally well tolerated [29–32].
Traditionally, the first indications of the effectiveness of a
therapeutic intervention have been changes in tumor vol-
ume and other clinical observable factors. These changes
occur late in the course of therapy, and the predictive power
of conventional response is, however, limited. Recent
studies suggest that the ADC of water, which is measured
noninvasively with MRI, is a sensitive and reliable way of
monitoring response to therapeutic interventions. To our
knowledge, there have been no experimental studies ad-
dressing the predictive value of early changes in ADC using
irradiation and chemotherapy. The purpose of this study is,
thus, to investigate whether ADC measurements can be
used in response prediction and early monitoring following
concomitant chemoradiotherapy.
Materials and Methods
Chemicals
Capecitabine (Xeloda; Roche, Hertfordshire, UK) powder
was suspended in vehicle [40 mM citrate buffer containing
5% (wt/vol) gum arabic, pH 6.0]. Liquid oxaliplatin (Eloxatin;
5 mg/ml) was purchased from Sanofi Synthelabo (Gentilly,
France). A stock solution of oxaliplatin was diluted five times
in 5% glucose solution for intravenous injection, as recom-
mended by the supplier.
Animals and Xenografts
Thirty-five female BALB/c nude mice (nu+/nu+) weighing
20 to 30 g and aged 6 to 8 weeks old were used in this
study. The National Committee on Research on Animal Care
approved the animal protocol, and the experiment was per-
formed according to Interdisciplinary Principles and Guide-
lines for the Use of Animals in Research, Marketing, and
Education (New York Academy of Science, New York, NY).
The mice were bred at the animal department of our in-
stitute and kept under specific pathogen-free conditions
at constant temperature (22–24jC) and humidity (30–
50%). The mice were given sterilized food and tap water
ad libitum. Tumor tissue fragments of the human colon
adenocarcinoma HT29 cell line, each measuringf 2  2 
2 (mm)3, were transplanted subcutaneously and bilaterally
into the rear flanks of mice to generate HT29 xenografts.
Treatment began 5 weeks after inoculation, with mice
bearing 100-mm3 to 340-mm3 subcutaneous tumors.
Assessment of Therapy Response
In axialT2-weighted fast spin-echoMR images, the tumors
appeared with high signal intensity relative to that of the
neighboring muscle (Figure 1). Manually circumscribed
regions of interest delineating the tumor volume in each slice
were multiplied by slice thickness to obtain tumor volumes.
Tumors were observed until the volume of one of the two
bilateral tumors on the rear flanks of the mice had reached
four times its pretreatment volume. The effectiveness of
therapy was evaluated by tumor doubling growth delay (Td)
and was calculated according to the following formula: Tumor
Doubling Growth Delay (Td) = T2x  C2x, where T2x and C2x
Figure 1. Axial T2-weighted MR image obtained with a fast spin-echo se-
quence of a mouse showing the HT29 tumor appearing bright relative to
surrounding tissues, allowing easy delineation of tumor borders.
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represent the number of days that treated and control tu-
mors take to double in size from the first day of treatment,
respectively. The expected Td in days of combined treatment
was calculated according to the following formula [33]:
Expected Tdmodality1+modality2 = Tdmodality1 + Tdmodality2, with
the modalities being capecitabine, oxaliplatin, and irra-
diation. The effect of the combined treatment (synergistic/
additive/antagonistic) was assessed by calculating the ratio
of observed Td divided by that of expected Td. The observed/
expected ratios were as follows: > 1 (combination was
synergistic), < 1 (combination was antagonistic), and 1 (com-
bination was additive) [33].
Treatment
The tumors were pooled and randomly allocated into three
groups: control (group 1), capecitabine (group 2), and cape-
citabine and oxaliplatin (group 3). Capecitabine (359 mg/kg
per day) or vehicle was administered by oral gavage 5 days/
week for 2 weeks (days 1–5 and 8–12). The animals in group
3 received oxaliplatin (10 mg/kg) as an intravenous injection
on days 2 and 9, whereas the mice in groups 1 and 2 were
given intravenous injections of 5% glucose solutions. Frac-
tionated irradiation (2 Gy  10 on days 2–6 and 9–13) was
delivered using a 60Co unit (Mobaltron 80; TEM Instruments,
Crawley, UK) at a dose rate of 0.6 Gy/min. The megavolt
beam produced by this cobalt source gives an initial dose
buildup with depth, resulting in a maximum dose at a
depth of 4 mm. To achieve a homogeneous dose deposition
within the tumor volume, a 5-mm-thick polystyrene bolus
was placed on top of the tumor. During radiotherapy, the left
flanks of anesthetized mice were irradiated, whereas the
rest of the body (including the contralateral tumor) was
kept outside the radiation field. Irradiation was performed
30 minutes after chemotherapy administration.
The mice were anesthetized with subcutaneous injections
of amixture of 2.4 mg/ml tiletamine and 2.4mg/ml zolazepam
(Zoletil vet; Virbac Laboratories, Carros, France), 3.8 mg/ml
xylazine (Narcoxyl vet; Roche, Basel, Switzerland), and
0.1 mg/ml butorphanol (Torbugesic; Fort Dodge Labora-
tories, Fort Dodge, IA), given as a dose of 25 mg/kg be-
fore chemotherapy and/or irradiation and 75 mg/kg before
MR examinations.
MRI
All experiments were performed on a 1.5-T GE Signa LS
clinical whole-body scanner (GE Medical Systems, Milwau-
kee, WI) equipped with a conventional gradient system
(30 mT/m). The anesthetized mouse was placed in a spe-
cial cradle and put into an in-house–built high-resolution
dedicated mouse MR coil (Figure 2). The loaded MR coil
was manually fine-tuned to the resonance frequency of the
MR scanner before the coil was placed inside the bore of the
magnet. All MR exams consisted of axial fast spin-echo
T2-weighted high-resolution images (TE eff = 85 milliseconds;
TR = 4000 milliseconds; echo train length (ETL) = 16; slice
thickness = 2 mm; image matrix = 192  160; field of view =
4 cm), diffusion tensor images (diffusion-weighted single-
shot fast spin echo TE eff = 78.7 milliseconds; TR = 5000 milli-
seconds; field of view = 14 cm; image matrix = 128  128;
slice thickness = 2 mm; interslice gap = 1 mm; b = 0 and
300 sec/mm2; with the following x, y, and z gradient directions
[1 0 1], [1 0 1], [0 11], [0 11], [11 0], [11 0]), and axial fast
spin-echo T2-weighted images with identical fields of view as
diffusion images. Preliminary diffusion tensor imaging of the
HT29 tumor model showed no appreciable diffusion anisot-
ropy at this spatial resolution, and it was reasonably assumed
that diffusion in this HT29 tumor model is isotropic (data not
published). Nonetheless, six diffusion gradient directions
were used to acquire data. By using the commercially avail-
able nICE software (Nordic Neurolab, Bergen, Norway),
acquired data were averaged on a pixel-by-pixel basis to
obtain isotropic ADCs. The mean ADC values of the tumors
were found by manually delineating the tumor tissue in T2-
weighted images and copying these regions of interest to
corresponding ADC maps. The change in ADC values fol-
lowing therapy was determined by calculating the percent
change in mean water ADC from baseline, with each mouse
serving as its own control. %ADC4, %ADC11, . . ., %ADC60
corresponds to the percent change in mean tumor ADC from
before therapy to day 4, day 11, . . ., day 60 after onset of
therapy, respectively.
Histologic Sections
After the last MR examination, the mice were sacrificed
by cervical dislocation, and the orientation of the tumors in
the magnet was marked on the surrounding tumor skin. The
tumors were immediately excised and fixed in 4% formalin
overnight. The tumorswere imbedded in paraffin, and a 5-mm-
thick section corresponding to the MR slice was stained
with hematoxylin and eosin (HE). Necrotic fraction was found
in all HE stains.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0
(SPSS, Cary, NC). The Kolmogorov-Smirnov test was ap-
plied to test for normality of tumor volumes and ADC values.
Two of the tumors in the experiment did not double their
volumes during the 60 days that the experiment lasted,
and their tumor doubling times were set to the maximum
Figure 2. In-house–built capacitive overlap transmit – receive MR mouse coil
for the imaging of small animals with a clinical whole-body scanner.
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observation period. Differences in tumor doubling growth
delays between treatment groups were compared using
one-way analysis of variance (ANOVA) and t-test. Pearson’s
correlation test was used to analyze whether the correlation
between two variables was significant. A significance level of
5% was used in all statistical analyses.
Results
Tumor Growth Curves
Statistical normality analysis with the Kolmogorov-
Smirnov test revealed that tumor volumes were normally
distributed before the onset of therapy (P = .34). The re-
sponse of HT29 xenografts to irradiation alone and in
combination with capecitabine and oxaliplatin is shown in
Figure 3. Untreated exponentially growing xenografts (n = 8)
had a doubling time of 18.1 ± 1.7 days. For all HT29 xeno-
grafts receiving radiotherapy or chemoradiation, a significant
antitumor activity was observed (P < .05). As monotherapy,
radiation (n = 9) was most effective, with a tumor doubling
growth delay of 13.9 ± 4.0 days, followed by capecitabine
(Td = 7.0 ± 2.3 days; n = 13). Furthermore, the antitumor
activity of the capecitabine/oxaliplatin combination treatment
(Td = 14.1 ± 1.7 days; n = 10) was significantly greater than
that of capecitabine (n = 13) alone (P = .03). Radiotherapy
induced a significant antitumor effect in all HT29 xenografts
compared to their contralateral nonirradiated xenografts
(P < .01 in all three groups). The eight tumors receiving both
daily capecitabine and irradiation for 2 weeks showed a
tumor doubling growth delay of 26.5 ± 5.7 days. The most
substantial antitumor effect was observed for the combination
of capecitabine, oxaliplatin, and irradiation (n = 9), which
resulted in initial regression followed by slow regrowth, yield-
ing a tumor growth doubling delay of 30.1 ± 3.3 days. How-
ever, the difference in tumor doubling growth delay between
the capecitabine/irradiation and capecitabine/oxaliplatin/
irradiation groups is not statistically significant (P = .22).
In HT29 xenografts, the observed/expected Td ratio for
capecitabine and irradiation was 1.27, indicating that the
in vivo combination of these two modalities resulted in a
synergistic antitumor activity. The in vivo combination of
capecitabine/oxaliplatin and irradiation had an observed/
expected Td ratio of 1.07, indicating at least an additive effect
in HT29 xenografts.
ADCs
DW-MRI was used for monitoring the response of HT29
tumor xenografts to combined treatments of capecitabine,
oxaliplatin, and irradiation. Statistical analysis revealed a nor-
mal distribution of pretreatment ADC values (Kolmogorov-
Smirnov, P = .66), with a mean ADC value of 0.53 
103 mm2/sec (range, 0.45  103 to 0.63  103 mm2/
sec; n=57). ADCmaps and high-resolution axialT2-weighted
images from one of the treated animals before therapy,
during therapy, and at different times posttherapy are shown
in Figure 4. Changes in mean tumor ADC for nonirradiated
and irradiated tumors as a result of therapy are presented
in Figure 5, A and B. Pretreatment ADC values were not
significantly different between mice in the control group
and mice in the treated groups. For control tumors, there
were no statistically significant changes in mean tumor ADC
during the 9 weeks that the mice were monitored (P > .05 for
all time intervals). For all tumors, except those receiving
capecitabine (P = .06), the increase in mean tumor ADC
from baseline to day 11 was statistically significant (P < .05).
On day 18 (5 days after the therapy ended), ADC values
had returned to pretreatment levels.
Figure 3. In vivo efficacy of combined irradiation (2 Gy for five consecutive days, 5 days/week for 2 weeks starting on day 2), capecitabine (359 mg/kg per day,
5 days/week for 2 weeks starting on day 1), and oxaliplatin (10 mg/kg, days 2 and 9) against human colon cancer HT29 xenografts in nude mice: (A) control, (B)
capecitabine, and (C) capecitabine and oxaliplatin. All left-sided tumors received additional radiotherapy.
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Pairwise comparisons of %ADC11 for the five treatment
groups showed statistically significant differences between
capecitabine and capecitabine/oxaliplatin (P < .01) and
between capecitabine and capecitabine/irradiation (P <
.01). The differences in %ADC11 between capecitabine/
irradiation and capecitabine/oxaliplatin/irradiation and be-
tween capecitabine/oxaliplatin and capecitabine/oxaliplatin/
irradiation were not statistically significant.
There were no obvious correlations between the mean
tumor ADC before treatment and the observed tumor growth
delay for the five treated groups (Figure 6), with Pearson’s
correlation coefficients varying from  0.50 for capecitabine-
treated tumors to + 0.42 for irradiated tumors.
Within 4 days of therapy, there were no statistically sig-
nificant changes in mean tumor ADC (%ADC4) in the five
treatment groups. However, a positive, but not significant,
correlation between mean %ADC4 and mean ultimate tumor
delay (r = 0.77, P = .07) was observed. There was a positive
correlation between mean %ADC11 and mean tumor delay
for the treatment groups (r = 0.92, P < .01), indicating a linear
relationship between an early increase in tumor ADC and
the ultimate effectiveness of therapy (Figure 7).
HT29 xenografts treated with capecitabine/oxaliplatin
showed the same quantitative increase in mean %ADC11
as capecitabine/irradiation– treated tumors despite the
fact that capecitabine/oxaliplatin was less efficacious
than capecitabine/irradiation, with Td values of 14.1 and
26.5 days, respectively.
Tumor Histology
Histologic examination of HE stains showed that both
treated and control tumors had necrotic centers. The necrotic
fraction ranged from 12% to 84%. One-way ANOVA revealed
no statistical differences in necrotic fractions between the
six treatment groups (P = .81).
Discussion
Response to chemotherapy and/or radiotherapy may vary
between individual tumors, and some tumors even proliferate
during preoperative chemoradiation, suggesting a potential
benefit if therapy response parameters could be predicted
either before onset of therapy or early on during treatment.
Such means of prediction and early monitoring would leave
clinicians with the possibility of adjustments during the course
of therapy, thus individualizing therapeutic strategy, which
could affect patient survival. In this study, diffusion MRI was
found to be a possible and early surrogate marker of anti-
tumor effect in mice bearing HT29 xenografts and treated
Figure 4. T2-weighted MR images (top) and ADC maps (bottom) obtained before therapy, during therapy, and at different times posttherapy from one of the mice
that received combined oxaliplatin/capecitabine chemoradiation.
Figure 5. Changes in mean tumor ADC for nonirradiated (A) and irradiated
tumors (B) as a function of time. The ADC value of each tumor is normalized
with respect to the pretreatment ADC value. Chemoradiotherapy was given
from days 1 to 13, and consisted of oxaliplatin (10 mg/kg, days 2 and 9),
capecitabine (359 mg/kg per day, 5 days/week for 2 weeks starting on day 1),
and irradiation (2 Gy for five consecutive days, 5 days/week for 2 weeks
starting on day 2).
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with a combination of the 5-FU prodrug capecitabine, oxali-
platin, and irradiation.
A treatment strategy with weekly oxaliplatin, daily capeci-
tabine, and 2-Gy fractions of irradiation was chosen to mimic
clinical situation. All treatments resulted in delayed tumor
doubling time compared to the control group. Both oxaliplatin
and capecitabine are potent radiosensitizing drugs [25–28]
and, as expected, their radiosensitizing properties were
observed in this study when chemotherapy was combined
with irradiation, giving a significant increase in tumor dou-
bling growth delay compared to the irradiated cohort. The
combination of capecitabine and irradiation showed syner-
gistic antiproliferative efficacy with an observed/expected
tumor doubling growth delay ratio of 1.27. Capecitabine is
Figure 6. Mean pretreatment tumor ADC as a function of tumor doubling growth delay (Td) for HT29 xenografts treated with (A) capecitabine, (B) capecitabine/
oxaliplatin, (C) irradiation, (D) capecitabine/irradiation, and (E) capecitabine/oxaliplatin/irradiation. Solid lines represent linear regression fit lines.
Figure 7. Correlation between tumor doubling growth delay and ADC rise after 4 days (A) and 11 days (B) of therapy. ADC changes are given as percent changes
compared to the pretreatment value. The six treatment groups are as follows: control (.), capecitabine (z), capecitabine/oxaliplatin (n), irradiation (o),
capecitabine/irradiation (q), and capecitabine/oxaliplatin/irradiation (5). Error bars indicate SEM. Solid lines represent linear regression fit lines.
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converted to 5-FU in tumor cells by the enzyme thymidine
phosphorylase, which is upregulated in tumor tissue com-
pared to adjacent normal tissue [34], and the synergy be-
tween capecitabine and irradiation could be a result of
irradiation-induced increase in tumor levels of thymidine
phosphorylase expression in human xenografts [25]. The
antitumor effect of capecitabine and irradiation was en-
hanced by adding oxaliplatin, indicating a potential for further
improving antitumor efficacy for patients receiving preopera-
tive chemoradiation by integrating oxaliplatin into the stan-
dard 5-FU–based chemotherapy strategy in rectal cancer.
By setting the tumor doubling time of the two xenografts
(one in group 5 and one in group 6) that did not double their
volumes to the maximum observation period (60 days), the
antitumor effects in these two treatment groups are under-
estimated. Removal of these xenografts from the growth
curves would have further underestimated the effect of
these two therapeutic regimes. However, to avoid introducing
errors in the evaluation of changes in ADC as an early mea-
sure of therapeutic efficiency, data from these two xenografts
were excluded from these analyses.
DW-MRI provides information about microscopic struc-
tures such as cell density and integrity or necrosis. Thus, a
viable tumor can be differentiated from a necrotic tumor with
diffusion imaging in contrast to conventionalMRI. Cell density
and necrotic fractions are parameters that have been moni-
tored with diffusion MRI [35–38]. A tissue with high cellular
density shows a low ADC resulting from impeded mobility
of water protons by a higher amount of cell membranes,
whereas necrotic areas will appear as hyperintense areas
on ADC maps resulting from the rapid diffusion of water pro-
tons as a consequence of lost membrane integrity [35,36].
Figure 8 shows the T2-weighted MR images and ADC maps
of two HT29 xenografts with 20% and 80% necrotic fractions.
In most cases, the MR images showed some degree of
heterogeneity due to localized necrotic regions with high
water mobility/high signal on both T2-weighted images and
ADC maps. When using diffusion MRI for examining biologic
effects, usually only the tumor periphery of viable cells is of
interest, and successful separation between viable and ne-
crotic areas relies on the skills of the operator. The entire
tumor is easily delineated in T2-weighted images. Information
gathered from consideration of the entire tumor is readily
applicable to the clinical evaluation of treatment outcome.
Furthermore, failure to evaluate the entire tumor volume
might result in sampling errors related to tumor heterogeneity
(errors that are similar to those associated with invasive
methods) because the sampled region may not be represen-
tative of the entire tumor [38].
A potential shortcoming in this study is the use of a single
b value of 300 sec/mm2. We did not investigate the role of
different b values because a pilot study showed satisfactory
results with a b value of 300 sec/mm2 and because higher
b values are associated with greater reduction in signal and
lower image quality. But, as a quantitative parameter of
DW-MRI, ADC reflects not only diffusion but also perfusion
of microvessels [39]. Previous studies have shown that for
low b values (b < 100 sec/mm2), perfusion dominates diffu-
sion by a factor of 10 [39,40]. By using high b values, the
influence of perfusion is largely cancelled, and most of the
signal remaining in the image originates from molecules with
the lowest mobility, and the ADC value approximates true
diffusion. The use of low and high b values in the same set-
ting for the calculation of ADC could have provided more
specific information about underlying biologic mechanisms.
Echo-planar imaging sequences will give diffusion images
with good signal-to-noise ratio and low radiofrequency (RF)
power deposition, but gradient rephasing results in spatial
distortions from magnetic susceptibility effects, especially
near air interfaces [14]. This will give rise to anatomic mis-
match on coregistration with T2-weighted MR images. RF-
refocused single-shot fast spin-echo–based diffusion MR
acquisitions provide images without a significant degree of
spatial distortions.
In this study, we found no correlation between pretreat-
ment tumor ADC values and regrowth delay for individual
Figure 8. ADC maps (upper row) and T2-weighted images (bottom row) illustrating the differences between a tumor with a large necrotic central area (A) and a
tumor with mostly viable cells (B). Histologic analysis of corresponding tumor slices revealed necrotic fractions of 80% and 20%, respectively, in these two tumors.
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tumors (Figure 6). It is a prerequisite for comparing different
chemotherapy regimens in animal models that initial xeno-
grafts be similar so that observed effects are therapy-induced
effects and not effects originating from the initial composition
of necrosis, fibrosis, and viable cells in tumors. To the authors’
knowledge, there has been only one published clinical study
that shows a strong negative correlation between pre-
treatment ADCs and response to therapy for rectal carci-
nomas treated with chemoradiation [41]. In this study, mean
pretreatment ADC values ranged from 0.8  103 to 2.2 
103 mm2/sec, indicating large differences in the initial com-
position of individual tumors and, hence, also sensitivity to
therapy compared to xenografts in our experiment (0.4 
103 to 0.6 103mm2/sec). Necrotic tumors have highADC
values and are also known to be associated with poor
response to cancer treatment [41].
The therapeutic interventions in this study resulted in
increased water mobility in the tumors observed as a rise in
the mean tumor ADC, and 11 days after initialization, this
increase was significant for all treatment tumors except for
those receiving capecitabine only (P = .06). The increase in
tumor water diffusion is consistent with results from other
experimental tumors on treatment with other anticancer
drugs and gene therapy [7–13,42–45]. The underlying
mechanisms of changes in diffusion in tumors are not fully
understood, but MR data from different tumor types tend
to suggest that the density of viable cells might be the key
factor affecting water diffusion in tumors [7,35]. As a re-
sponse to therapy, tumor cells die and the membrane starts
to degrade; therefore, extracellullar water fraction increases
and gives an increased ADC value. It is tempting to extra-
polate that the therapy-induced increase in ADC values is
due to cell shrinkage, although the exact mechanism has not
yet been determined.
In our study, the increase in tumor ADC measured 11 days
after the onset of therapy (%ADC11) correlated with ultimate
tumor response, and the magnitude of change was directly
related to the effectiveness of the therapy. These results show
that diffusion imaging has the potential for the early assess-
ment of therapy response in individual patients. Because
many treatment regimes such as chemotherapy and radio-
therapy are frequently given in fractionated cycles, an early
assessment of therapeutic response during the initial phase of
administration would provide an opportunity to gauge opti-
mum dosage and would also provide feedback related to
optimum dose frequency. The sensitivity of diffusion MRI to
changes in tissue structure may also advance experimental
therapeutics by providing new tools for analyzing therapeu-
tics both in laboratory models and in clinical work.
Despite large differences in tumor doubling growth delay
between capecitabine/irradiation–treated and capecitabine/
oxaliplatin–treated xenografts, their %ADC11 values were
similar. This might be an indication of the quantitative amount
of ruptured cell membranes (lysis) being equal in the two
groups. Exposure to radiation has been shown to induce
cellular senescence in some tumor cell lines [46]. Radiation-
induced senescence would contribute to the growth delay of
tumors without necessarily influencing the ADC. However, it
is not known if radiation-induced senescence occurs in the
HT29 xenografts used in this study, but the existence of such
a mechanism in the capecitabine/irradiation group could
explain the reduced tumor growth in these xenografts com-
pared to that in the capecitabine/oxaliplatin group.
The full prognostic value of diffusion MRI remains unclear,
and further work is required to determine whether the ob-
served changes in tumor diffusion are a universal response to
successful cell killing and to delineate the kinetics of diffusion
changes, but our results suggest that early changes in ADC
could yield clinically important information in the prediction of
therapy response for rectal cancer.
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